We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4911:TSEShiseido Company,Limited Analysis

Data as of 2026-06-18 - not real-time

¥2,592.50

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Shiseido is trading below its short‑term moving average but still above the long‑term average, indicating a mild pull‑back within a broader uptrend. The RSI sits in the low‑forties, suggesting limited downside momentum, while the MACD shows a bullish crossover with a positive histogram, hinting at potential upside. Volume has been tapering, and the price is hovering near a key support level, making the near‑term outlook cautious. The market sentiment index reads Extreme Greed, reflecting strong investor appetite despite the neutral technical trend.
Fundamentally, the DCF model values the stock well below the current price, implying an overvalued condition, yet the forward PE is moderate and the dividend yield is attractive with a low payout ratio, supporting dividend sustainability. Profitability metrics remain weak, with a negative trailing EPS and modest revenue growth, but cash generation is solid and the balance sheet shows ample liquidity. Given the high 30‑day volatility and a beta close to zero, price swings are expected to be pronounced but not strongly correlated with broader market moves. Overall, the blend of brand strength, defensive sector positioning, and dividend appeal offsets the valuation gap for medium‑term investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near technical support
  • decreasing volume indicating cautious participation
  • neutral trend despite bullish MACD signal

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • attractive dividend yield with low payout ratio
  • solid cash flow and liquidity
  • brand strength in defensive consumer sector

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • overvalued relative to DCF fair value
  • persistent profitability challenges
  • defensive positioning and diversified product portfolio

Key Metrics & Analysis

Financial Health

Revenue Growth1.60%
Profit Margin-3.70%
P/E Ratio20.9
ROE-5.58%
ROA1.19%
Debt/Equity55.47
P/B Ratio1.7
Op. Cash Flow¥106.6B
Free Cash Flow¥62.9B

Technical Analysis

TrendNeutral
RSI41.0
Support¥2,466.50
Resistance¥2,832.50
MA 20¥2,607.58
MA 50¥2,957.30
MA 200¥2,720.61
MACDBullish
VolumeDecreasing
Fear & Greed Index88.5

Valuation

Fair Value¥1,599.97
Target Price¥3,190.71
Upside/Downside23.07%
GradeOvervalued
TypeBlend
Dividend Yield2.35%

Risk Assessment

Beta-0.09
Volatility41.69%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.